跳至主要内容
临床试验/NCT05692596
NCT05692596进行中(未招募)不适用

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

H. Lee Moffitt Cancer Center and Research Institute1 个研究点 分布在 1 个国家目标入组 317 人开始时间: 2022年10月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
317
试验地点
1
主要终点
Database creation

研究概览

简要总结

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older
  • Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
  • Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
  • Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

排除标准

  • 未提供

研究组 & 干预措施

All participants

Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.

干预措施: Data collection (Other)

结局指标

主要结局

Database creation

时间窗: 24 months

A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验